Clinical data from 424 patients with various stages of prostate tumors including N0: no regional lymph-node metastasis (n = 345), and N1: metastases in 1 to 3 axillary lymph nodes (n = 79) was compared with 52 controls showed significantly higher levels of the MD2 transcript in tumors with lymph-node metastasis (Fig. 1C). The gene discussed is LY96; the disease is prostate neoplasm.